

4 November 2022

Botanix announces upcoming presentation at American Society of Nephrology Conference

Key highlights

- Botanix announces presentation of an abstract outlining outcomes and costs associated with central venous catheter-related *S. aureus* bloodstream infections in hemodialysis patients with *S. aureus* nares colonization and diabetes mellitus, at the upcoming American Society of Nephrology Annual Meeting (ASN 2022)
- The abstract (SA-PO453:) “Outcomes and Costs Associated with Central Venous Catheter-Related *S. aureus* Bloodstream Infections in Hemodialysis Patients with *S. aureus* Nares Colonization and Diabetes Mellitus”, will be presented by the author, Professor Tom Lodise on November 5, 2022

Philadelphia and Phoenix US, 4 November 2022: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to announce an upcoming data presentation at the upcoming American Society of Nephrology Annual Meeting (ASN 2022) in Orlando, Florida on November 3-6, 2022.

The abstract entitled “*Outcomes and Costs of Central Venous Catheter-Related S. aureus Bloodstream Infections in Hemodialysis Patients with S. aureus Nares Colonization and Diabetes Mellitus*” will be presented by the author, Professor Tom Lodise, on November 5, 2022, from 10am to 12 noon EDT in the Exhibit Hall, Orange County Convention Center, West Building in the Dialysis Category.

The modeling study outlined in the Abstract explored the annual costs to insurance companies (payers) associated with central venous catheter (CVC) related *S. aureus* bloodstream infections in CVC-hemodialysis patients, with intranasal *S. aureus* colonization and diabetes mellitus.

The study population for this modeling study consisted of approximately 45,000 patients with diabetes mellitus as the primary cause of end-stage renal disease, who start in-center CVC-hemodialysis in the US each year. Data indicates that approximately 18,000 of these CVC-hemodialysis patients with diabetes are colonized with *S. aureus* in their nares (nostrils). Among the 18,000 CVC-hemodialysis patients with diabetes mellitus and *S. aureus* nares colonization, approximately 9.3% of them will have a CVC-related *S. aureus* bloodstream infection every 12 weeks. Attributable payer costs associated with managing these CVC-related *S. aureus* bloodstream infections are projected to exceed US\$229 million annually.

Author Professor Tom Lodise, remarked: “Data indicate that 18,000 of the 45,000 annual incident CVC-hemodialysis patients with diabetes mellitus as primary cause of end-stage renal disease are colonized with *S. aureus* in their nares. The annual morbidity, mortality, and healthcare costs associated with CVC-related *S. aureus* bloodstream infections in these patients as the primary cause of end-stage renal disease, are substantial.

The research we have completed projects that costs to payers, (including Government insurers such as Medicare), exceed more than US\$229 million annually. New therapies are urgently needed to prevent CVC-related S. aureus bloodstream infections in this patient population."

ASN is the world's premier nephrology meeting and is expected to draw thousands of kidney professionals from across the globe at Kidney Week 2022 in Orlando on November 3 to 6.

Dr Jamie P. Dwyer, MD, Professor of Medicine, University of Utah Clinical and Translational Sciences Institute, Co-founder of Innovative Renal Care also remarked: *"The hemodialysis patient population is highly vulnerable to infection, in particular those patients with S. aureus nares colonization and diabetes mellitus as the primary cause of End Stage Renal Disease.*

The costs of treating bloodstream infections in these patients places a considerable burden on the healthcare system. There is a need for novel therapeutics for intranasal decolonization of S. aureus to reduce the risk of S. Aureus bloodstream infections among this high-risk hemodialysis patient population with diabetes mellitus as the primary cause of ESRD."

This ASX announcement is authorised for release by the Board

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is committed to the development of novel treatments for a range of common skin diseases. The Company has a mature dermatology pipeline with its first product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis, filed for FDA approval in Q3 CY2022 with approval expected in Q3 2023. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis.

Botanix leverages its proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

HACK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and applicable US state securities laws.